Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
Nippon Boehringer Ingelheim’s Jardiance (empagliflozin) fell to the second spot in the Japanese SGLT2 market in 2021, but its planned label expansion into chronic kidney disease (CKD) will help it retrieve the No. 1 crown, Chairman and President Yoshiaki Aono…
To read the full story
Related Article
- Nippon Boehringer Ingelheim Logs 6.7% Sales Rise in 2021
April 19, 2022
- Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
- Boehringer’s Japan Pharma Sales Rise 3.1% in 2020 on Ofev, Jardiance
April 28, 2021
- Boehringer’s Japan Sales Up 5.4% in 2020 as Ofev, Jardiance Fare Well
March 25, 2021
- Yoshiaki Aono to Be Promoted to Chairman and President of Nippon BI in September
July 10, 2020
BUSINESS
- Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
- ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
- Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…